Bioequivalence evaluation of two brands of rivastigmine of different salt forms, an acetylcholinesterase inhibitor for the treatment of Alzheimer's disease, in healthy Beagle dogs

Pharmazie

Volumn 66, Issue 8, 2011, Pages 590-593

  Shen, Cidan ^a   Yang, Bei ^a   Zhou, Tao ^a   Duan, Gengli ^a   Yu, Yingjia ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

RIVASTIGMINE; SODIUM CHLORIDE; CARBAMIC ACID DERIVATIVE; CHOLINESTERASE INHIBITOR;

ALZHEIMER DISEASE; ANALYSIS OF VARIANCE; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; MALE; MASS FRAGMENTOGRAPHY; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; TIME TO MAXIMUM PLASMA CONCENTRATION; ANIMAL; CHEMISTRY; DOG; HALF LIFE TIME; PHARMACOKINETICS; STATISTICAL ANALYSIS;

ALZHEIMER DISEASE; ANIMALS; AREA UNDER CURVE; CHOLINESTERASE INHIBITORS; DATA INTERPRETATION, STATISTICAL; DOGS; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HALF-LIFE; MALE; PHENYLCARBAMATES; THERAPEUTIC EQUIVALENCY;

EID: 80053298794     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2011.1030     Document Type: Article

References (8)

1. Wong S (2006) FDA approves rivastigmine tartrate for the treatment of Parkinson's disease dementia. CNS Spectrum 11: 576-576.
2. Bhatt J, Subbaiah G, Kambli S, Shah B, Nigam S, Patel M, Saxena A, Baliga A, Parekh H, Yadav G (2007) A rapid and sensitive liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the estimation of rivastigmine in human plasma. J. Chromatogr. B 852: 115-121. (Pubitemid 46830101)
3. Bullock R, Cameron A (2002) Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson's disease: a case series. Curr Med Res Opin 18: 258-264. (Pubitemid 35014541)
4. Ballmaier M, Casamenti F, Scali C, Mazzoncini R, Zoli M, Pepeu G, Spano PF (2002) Rivastigmine antagonizes deficits in prepulse inhibition induced by selective immunolesioning of cholinergic neurons in nucleus basalis magnocellularis. Neuroscience 114: 91-98. (Pubitemid 35247492)
5. Kennedy JS, Polinsky RJ, Johnson B, Loosen P, Enz A, Laplanche R, Schmidt D, Mancione LC, Parris WCV, Ebert MH (1999) Preferential cerebrospinal fluid acetylcholinesterase inhibition by rivastigmine in humans. J Clin Psychopharmacol 19: 513-521.
6. Kurz A, Farlow M, Quarg P, Spiegel R (2004) Disease stage in Alzheimer disease and treatment effects of rivastigmine. Alzheimer Dis Assoc Disord 18: 123-128. (Pubitemid 39202187)
7. Hauschke D, Steinijans VW, Eiletti EA (1990)Adistribution-free procedure for the statistical analysis of bioequivalence studies. Int J Clin Pharmacol Ther Toxicol 28: 72-78. (Pubitemid 20098974)
8. Schulz HU, Steinijans VW (1992) Striving for standards in bioequivalence assessment: a review. Int J Clin Pharmacol Ther Toxicol 30 (Suppl.1): S1-S6.